Mylan N.V in the United States Finalizes EpiPen Settlement for US$ 465 Million
Mylan NV- a global specialty and generic pharmaceutical firm located in the United States finalized a settlement of US$ 465 million on August 17, 2017, resolving the claims imposed by the United States Justice Department that the company overcharged the government for offering its EpiPen emergency treatment for allergy. This had become the center of an argument because of price augmentation.
On Thursday, the United States Attorney’s Office based in Massachusetts declared the accord, which was criticized by certain members from congress as taking the matter lightly and being extremely easy on the drug manufacturing firm. It came almost ten months after the pharmaceutical company Mylan stated that it has reached a deal.
The EpiPen settlement resolved allegations that Mylan dodged higher repayments to Medicaid programs in the state by purposely miscataloging EpiPen as a generic medication, even when it was priced and marked as a brand-name medication. William Weinreb- the Acting Attorney of the United States mentioned in a statement that, “tax payers rightfully expect firms like Mylan that get payments from taxpayer-sponsored programs to meticulously follow the set rules and guidelines.” Mylan, however did not confess about any wrongdoing under the deal. The company said it will recategorize EpiPen and pay the refundable amount to its fresh classification effective from April 1, 2017.
Heather Bresch, Chief Executive of Mylan mentioned in a statement that “closing this issue at the earliest will be the right step to take for Mylan as well as our stakeholders to permit us to move ahead with our business.” Mylan acquired EpiPen in 2007. EpiPen is a typical handheld device which is used for the treatment of life-threatening and dangerous allergic reactions. It automatically injects a dosage of epinephrine in the patient’s body. Mylan faced trouble last year when it increased the price of EpiPens to US$ 600 which was US$ 100 up to 2008. This enraged the consumers thus making the matter a topic of the current debate in the United States over high costs of prescription medications.
You may be interested
Digital Health Market Expansion to be Persistent During 2026Albert R - October 12, 2018
"The Digital Health Market is expected to have a highly positive outlook for the next five years 2018-2026 according to a recently released Digital Health Market research…
Medical Grade Hydrogel Market Poised to Take Off by 2026Albert R - October 12, 2018
"The Medical Grade Hydrogel Market is expected to have a highly positive outlook for the next five years 2018-2026 according to a recently released Medical Grade Hydrogel…